RT Journal Article
SR Electronic
T1 The dark side of SARS-CoV-2 rapid antigen testing: screening asymptomatic patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.24.21256040
DO 10.1101/2021.04.24.21256040
A1 Giorgia Caruana
A1 Laure-Line Lebrun
A1 Oriane Aebischer
A1 Onya Opota
A1 Luis Urbano
A1 Mikael de Rham
A1 Oscar Marchetti
A1 Gilbert Greub
YR 2021
UL http://medrxiv.org/content/early/2021/04/27/2021.04.24.21256040.abstract
AB Most of the reports describing SARS-CoV-2 rapid antigen tests (RATs) performances derive from COVID-19 symptomatic subjects in outpatient settings during periods of highest incidence of infections and high rates of hospital admissions. Here we investigated the role of RATs in an Emergency Department, as a screening tool before admission for COVID-19 asymptomatic patients. Each patient was screened with two simultaneous nasopharyngeal swabs: one immediately analyzed at the bedside using RAT and the other sent to the laboratory for RT-PCR analysis. A total of 116 patients were screened at hospital admission in a 250-bed community hospital in Morges (EHC), Switzerland. With a disease prevalence of 6% based on RT-PCR results, RAT detected only two out of seven RT-PCR positive patients (sensitivity 28.6%) and delivered two false positive results (specificity 98.2%), thus resulting not fiable enough to be used as a screening method in this clinical scenario.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe fact to use the antigen test and the Rt-PCR sequentially was not a research project, but corresponded to good clinical practices that followed the recommendations of the Swiss Society of Microbiology (https://www.swissmicrobiology.ch/en/sars-cov-2-antigen-tests). Regarding antigen tests comparison on left over of the viral transport medium, Professor Dominique Sprumont (dominique.sprumont@vd.ch<mailto:dominique.sprumont@vd.ch>), the president of the ethical committee of the Vaud canton (CER-VD), proposed the following: 'The data on the fiability of the different antigen assays were obtained during a quality enhancement project. According to national law (Swiss Federal Act on Human Research), the performance and publishing the results of such a project can be done without asking the permission of the competent research ethics committee.'Funding StatementThe authors did not receive any financial support for this work. All authors had full access to all the data in the study and they accept responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The fact to use the antigen test and the Rt-PCR sequentially was not a research project, but corresponded to good clinical practices that followed the recommendations of the Swiss Society of Microbiology (https://www.swissmicrobiology.ch/en/sars-cov-2-antigen-tests). Regarding antigen tests comparison on left over of the viral transport medium, according to Professor Dominique Sprumont (dominique.sprumont@vd.ch<mailto:dominique.sprumont@vd.ch>), the president of the ethical committee of the Vaud canton (CER-VD): 'The data on the fiability of the different antigen assays were obtained during a quality enhancement project. According to national law (Swiss Federal Act on Human Research), the performance and publishing the results of such a project can be done without asking the permission of the competent research ethics committee.' All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available but they will be shared upon request for peer-review purposes.